Apurva A. Desai - Concepedia

Author

Apurva A. Desai

Also Known As

A Desai, A. Desai, A.A. Desai, Apurva A Desai, Apurva A. Desai, Apurva Desai, Avni Pravinbhai Desai, Edelman, Martin J., McLeod, Howard L.

Publications

8.5K

Citations

H-Index

Concepts

All Affiliations

University of Chicago Cancer Research Center Cleveland Clinic Bayer (United States)The University of Texas MD Anderson Cancer Center

About

Apurva A. Desai is an author at University of Chicago specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	644
2	Health Sciences	1	1	14
3	Allergy	1	1	72
4	Cell Biology	1	1	168
5	Endocrinology	1	1	42

Apurva A. Desai

Publications

8.4K

Citations

H-Index

Page 1

	Year	Citations
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Bernard Escudier, Tim Eisen, Walter M. Stadler, New England Journal of Medicine	2007	4.8K
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Bernard Escudier, Tim Eisen, Walter M. Stadler, Journal of Clinical Oncology	2009	1.1K
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Mark J. Ratain, Tim Eisen, Walter M. Stadler, Journal of Clinical Oncology	2006	1K
Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity Charles M. Rudin, Wanqing Liu, Apurva A. Desai, Journal of Clinical Oncology	2008	217
Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301 Antonius A. Miller, Daryl J. Murry, Kouros Owzar, Journal of Clinical Oncology	2009	207
A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter Wanqing Liu, Federico Innocenti, Michael H. Wu, Cancer Research GeneticsHuman PolymorphismGene CharacterizationCancer BiologyTumor Biology	2005	168
Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes Federico Innocenti, Wanqing Liu, Peixian Chen, Pharmacogenetics and Genomics	2005	113
A high rate of venous thromboembolism in a multi‐institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma Apurva A. Desai, Nicholas J. Vogelzang, Brian I. Rini, Cancer	2002	112
A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies Christine Hartford, Apurva A. Desai, Linda Janisch, Clinical Cancer Research	2009	88
Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma Scot Ebbinghaus, Maha Hussain, Nizar Tannir, Clinical Cancer Research	2007	87

Page 1